ABLYNX (Euronext Brussels:ABLX)
ABLYNX is a biopharmaceutical company engaged in the discovery and development of Nanobodies ® , a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease.
Company Website: http://www.ablynx.com/
28395 | Sponsor | 03/19/2024 7:24:18 AM |
Be the first to post on ABLYNX (D) ABLX